评估多种癌症早期检测测试:一个关于复发更新阶段结果的论点
Matthew E J Callister1,2, Emma J Crosbie3, Philip A J Crosbie4
1Consultant Respiratory Physician, Leeds Teaching Hospitals, Leeds, UK. matthew.callister@nhs.net.
British journal of cancer
|September 19, 2023
概括
多种癌症早期检测 (MCED) 测试对彻底改变癌症诊断的前景充满希望. 然而,仅仅依靠晚期癌症发病率的降低,可能无法充分捕捉微转移性疾病带来的好处.
科学领域:
- 在瘤学瘤学.
- 诊断医学 诊断医学
- 临床试验 临床试验
背景情况:
- 多种癌症早期检测 (MCED) 试验为癌症诊断和治疗提供了变革性的潜力.
- 该NHS-Galleri试验调查了一个特定的MCED测试,使用晚期癌症发病率的降低作为主要终点.
- 这一终点假设晚期癌症的减少与癌症死亡率的降低直接相关.
研究的目的:
- 批判性地评估NHS-Galleri试验的主要终点.
- 解决使用晚期癌症绝对发病率作为死亡率福利的替代品的潜在局限性.
- 提出一个调整的试验结果衡量标准,更准确地反映MCED测试对癌症死亡率的影响.
主要方法:
- 分析在MCED试验中使用晚期癌症发病率作为主要终点的假设.
- 考虑微转移性疾病的生物现象及其对癌症进展的影响.
- 为调整的试验结果指标开发一个概念框架.
主要成果:
- 减少晚期癌症发病率直接等同于减少癌症死亡率的假设可能是有缺陷的.
- 微转移性疾病可能会使晚期癌症发病率作为治疗疗效的唯一指标的解释变得复杂.
- 建议对试验结果进行调整,以更好地与预期的减少癌症死亡率保持一致.
结论:
- 目前NHS-Galleri试验的主要终点可能无法完全捕捉MCED测试的死亡率益处.
- 考虑到微转移性疾病对于更准确地评估MCED测试疗效至关重要.
- 一个调整的结果测量是必要的,以更好地反映MCED测试对癌症死亡率的真正影响.
相关概念视频
01:21Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
01:20Comparing the Survival Analysis of Two or More Groups
220
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
220